Individuals harboring germline mutations in the tumor suppressor gene von Hippel-Lindau (VHL) exhibit an increased susceptibility to a variety of tumors including renal carcinoma, hemangio-blastoma of the central nervous system and pheochromo-cytoma. The Elongin (SIII) complex has been identified as the functional target of the VHL protein. Elongin (SIII) is a heterotrimer composed of a transcriptional active subunit designated Elongin A and two regulatory subunits designated Elongin B and Elongin C. VHL functions by binding to the Elongin B and C subunits, inhibiting the transcriptional efficacy of the Elongin (SIII) complex. The VHL protein migrates with an apparent molecular weight of 38 kDa. The Elongin A subunit is 773 amino acids in length and has an apparent molecular weight of 110 kDa, while Elongin B and C are 18 kDa and 15 kDa proteins, respectively.

Transcription elongation factor B polypeptide 3; RNA polymerase II transcription factor SIII subunit A1; SIII p110; Elongin A; EloA; Elongin 110 kDa subunit; TCEB3;

q14241

Human

WB,IHC

WB 1:500-1:1000
IHC 1:50-1:200

~ 100 kDa

Rabbit

This antibody detects endogenous levels of Elongin A1 protein.

Synthetic peptide, corresponding to amino acids 98-142 of Human Elongin A1.

Polyclonal

Rabbit IgG

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

PBS with 0.02% sodium azide, 50% glycerol, pH7.2

1mg/ml

Store at 4℃ short term,and store at -20℃ long term. Avoid freeze-thaw cycles.